Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bansal, Ritika
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease	Recruiting	3	2000	Europe, Canada, RoW	Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo	The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center	Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease	06/27	12/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bansal, Ritika
TRACK, NCT03969953 / 2020-000334-17: Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease Jan 2025 - Dec 2025: From TRACK trial for cardiovascular disease in chronic kidney disease	Recruiting	3	2000	Europe, Canada, RoW	Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Placebo	The George Institute, George Clinical Pty Ltd, Bayer, Centre Hospitalier Régional Universitaire de Nancy, King Abdullah International Medical Research Center	Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease	06/27	12/27